메뉴 건너뛰기




Volumn 73, Issue 4, 2014, Pages 737-747

Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

Author keywords

Exposure response; Gastric cancer; Gastroesophageal junction cancer; Population pharmacokinetics; Trastuzumab

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB;

EID: 84898058380     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2400-5     Document Type: Article
Times cited : (101)

References (22)
  • 1
    • 0022647432 scopus 로고
    • The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
    • 3012781 10.1126/science.3012781
    • Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646
    • (1986) Science , vol.232 , pp. 1644-1646
    • Akiyama, T.1    Sudo, C.2    Ogawara, H.3    Toyoshima, K.4    Yamamoto, T.5
  • 2
    • 0022399581 scopus 로고
    • Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
    • 2999974 10.1126/science.2999974
    • Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
    • (1985) Science , vol.230 , pp. 1132-1139
    • Coussens, L.1    Yang-Feng, T.L.2    Liao, Y.C.3
  • 3
    • 50849123421 scopus 로고    scopus 로고
    • HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
    • 18441328 10.1093/annonc/mdn169
    • Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
    • (2008) Ann Oncol , vol.19 , pp. 1523-1529
    • Gravalos, C.1    Jimeno, A.2
  • 4
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • 3798106 10.1126/science.3798106
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 5
    • 20044372721 scopus 로고    scopus 로고
    • Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
    • 15668283 10.1093/annonc/mdi064
    • Tanner M, Hollmén M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
    • (2005) Ann Oncol , vol.16 , pp. 273-278
    • Tanner, M.1    Hollmén, M.2    Junttila, T.T.3
  • 6
    • 44249092320 scopus 로고    scopus 로고
    • Assessment of a HER2 scoring system for gastric cancer: Results from a validation study
    • 18422971 10.1111/j.1365-2559.2008.03028.x
    • Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
    • (2008) Histopathology , vol.52 , pp. 797-805
    • Hofmann, M.1    Stoss, O.2    Shi, D.3
  • 7
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • ToGA Trial Investigators et al. 20728210 10.1016/S0140-6736(10)61121-X
    • Bang YJ, van Cutsem E, Feyereislova A, ToGA Trial Investigators et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3
  • 8
    • 0034954242 scopus 로고    scopus 로고
    • Assessment of actual significance levels for covariate effects in NONMEM
    • 11468939 10.1023/A:1011527125570
    • Wählby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252
    • (2001) J Pharmacokinet Pharmacodyn , vol.28 , pp. 231-252
    • Wählby, U.1    Jonsson, E.N.2    Karlsson, M.O.3
  • 9
    • 75149145545 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development
    • 20055530 10.2165/11530560-000000000-00000
    • Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24:23-39
    • (2010) BioDrugs , vol.24 , pp. 23-39
    • Mould, D.R.1    Green, B.2
  • 10
    • 77956388219 scopus 로고    scopus 로고
    • Population pharmacokinetics of therapeutic monoclonal antibodies
    • 20818831 10.2165/11535960-000000000-00000
    • Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
    • (2010) Clin Pharmacokinet , vol.49 , pp. 633-659
    • Dirks, N.L.1    Meibohm, B.2
  • 11
    • 78049485263 scopus 로고    scopus 로고
    • Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    • 21351269 10.1002/ijc.25516
    • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
    • (2010) Int J Cancer , vol.127 , pp. 2893-2917
    • Ferlay, J.1    Shin, H.R.2    Bray, F.3    Forman, D.4    Mathers, C.5    Parkin, D.M.6
  • 14
    • 0029160004 scopus 로고
    • Effective half-life in clinical pharmacology
    • 8522631 10.1002/j.1552-4604.1995.tb04117.x
    • Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763-766
    • (1995) J Clin Pharmacol , vol.35 , pp. 763-766
    • Boxenbaum, H.1    Battle, M.2
  • 15
    • 84877865099 scopus 로고    scopus 로고
    • The combination of exposure-response and case-control analyses in regulatory decision making
    • 23436261 10.1177/0091270012445206
    • Yang J, Zhao H, Garnett C et al (2013) The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 53:160-166
    • (2013) J Clin Pharmacol , vol.53 , pp. 160-166
    • Yang, J.1    Zhao, H.2    Garnett, C.3
  • 16
    • 32444438731 scopus 로고    scopus 로고
    • Elimination mechanisms of therapeutic monoclonal antibodies
    • 16478695 10.1016/S1359-6446(05)03638-X
    • Tabrizi MA, Tseng CM, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88
    • (2006) Drug Discov Today , vol.11 , pp. 81-88
    • Tabrizi, M.A.1    Tseng, C.M.2    Roskos, L.K.3
  • 17
    • 4143050397 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    • 15210739 10.1200/JCO.2004.11.061
    • Rowinsky EK, Schwartz GH, Gollob JA et al (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015
    • (2004) J Clin Oncol , vol.22 , pp. 3003-3015
    • Rowinsky, E.K.1    Schwartz, G.H.2    Gollob, J.A.3
  • 18
    • 84937027579 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 29 Oct 2013
    • European Medicines Agency (2012) EPAR summary for the public http://www.ema.europa.eu/docs/en-GB/document-library/EPAR -Summary-for-the- public/human/000278/WC500049819.pdf Accessed 29 Oct 2013
    • (2012) EPAR Summary for the Public
  • 19
    • 23244455101 scopus 로고    scopus 로고
    • Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer
    • 15868146 10.1007/s00280-005-1026-z
    • Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369
    • (2005) Cancer Chemother Pharmacol , vol.56 , pp. 361-369
    • Bruno, R.1    Washington, C.B.2    Lu, J.F.3    Lieberman, G.4    Banken, L.5    Klein, P.6
  • 20
    • 84889835285 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics
    • S.C. Gad (eds) Wiley Hoboken 10.1002/9780470117118.ch3b
    • Mager DE, Ramanathan M (2007) Preclinical pharmacokinetics. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. Wiley, Hoboken, pp 253-278
    • (2007) Handbook of Pharmaceutical Biotechnology , pp. 253-278
    • Mager, D.E.1    Ramanathan, M.2
  • 21
    • 78650381707 scopus 로고    scopus 로고
    • Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
    • 3019132 21176210 10.1186/1475-2891-9-69
    • Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69
    • (2010) Nutr J , vol.9 , pp. 69
    • Gupta, D.1    Lis, C.G.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.